This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Fasiglifam

Takeda Pharmaceutical Company Ltd

Drug Names(s): TAK875, TAK-875

Description: Fasiglifam is an oral, glucose-dependent insulin secretagogue in development for diabetes mellitus.

Deal Structure: Takeda in-licensed TAK-875 from Amgen.

Partners: Amgen, Inc.


Fasiglifam News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug